0001179110-14-008886.txt : 20140521
0001179110-14-008886.hdr.sgml : 20140521
20140521185227
ACCESSION NUMBER: 0001179110-14-008886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140519
FILED AS OF DATE: 20140521
DATE AS OF CHANGE: 20140521
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ertel Steven D
CENTRAL INDEX KEY: 0001586752
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 14861880
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2014-05-19
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586752
Ertel Steven D
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Chief Business Officer
Common Stock
2014-05-19
4
M
0
2500
0.40
A
30156
D
Common Stock
2014-05-19
4
S
0
2400
31.49
D
27756
D
Common Stock
2014-05-19
4
S
0
100
32.35
D
27656
D
Common Stock
2014-05-19
4
M
0
7500
5.08
A
35156
D
Common Stock
2014-05-19
4
S
0
7109
31.48
D
28047
D
Common Stock
2014-05-19
4
S
0
391
32.19
D
27656
D
Option to Purchase Common Stock
0.40
2014-05-19
4
M
0
2500
0
D
2016-01-18
Common Stock
14375
11875
D
Option to Purchase Common Stock
5.08
2014-05-19
4
M
0
7500
0
D
2018-03-27
Common Stock
56250
48750
D
The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $31.84, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.84, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.10 to $32.35, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
/s/ Kevin F. McLaughlin, as attorney-in-fact for Steven D. Ertel
2014-05-21